Forest/Lipha Acamprosate Indication Should Be Limited To Abstinent Patients
Forest/Lipha's acamprosate should be limited to patients who are abstinent from alcohol prior to taking the drug, FDA's Psychopharmacologic Drugs Advisory Committee suggested May 10
You may also be interested in...
A subgroup analysis of European trial data for Forest/Lipha's acamprosate would help clarify whether trends seen in certain U.S. clinical trial subpopulations are meaningful, FDA's Psychopharmacologic Drugs Advisory Committee suggested May 10
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011